An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed

Trial ID or NCT#

NCT00497770

Status

not recruiting iconNOT RECRUITING

Purpose

This large, non-randomized observational study is being conducted to provide data about the impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of non-small cell lung cancer (NSCLC) in a routine medical care setting.

Official Title

Non-small Cell Lung Cancer: The Impact of Ethnic Origin on Patients Being Treated Second Line With Pemetrexed - An Observational Study

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Non-small cell lung cancer (NSCLC) (any histologic type)* Stage IIIB or IV disease* Should have had 1 line of chemotherapy for Metastatic disease* Adequate hematologic, hepatic and renal function* Measurable or evaluable disease
Exclusion Criteria:
  1. * Pregnant or lactating females
View All Criteria
Show Less

Investigator(s)

Heather A Wakelee
Heather A Wakelee
Medical oncologist, Thoracic specialist
Winston Chen and Phyllis Huang Professor

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061

View on ClinicalTrials.gov